Logistics Live: Conversations & Insights on the Global Supply Chain

✓

Klaim

Energy, of course, powers the world. And harnessing that energy is an extraordinarily challenging task, involving massive equipment and sensitive parts that must travel to and from the furthest reaches of the globe. From oil rigs in the North Sea to wind farms off the U.S. coast, securing historica…

In this episode, Driving change: Adapting to the evolving automotive supply chain – we tackle the historical global nature of the automotive supply chain and potential country-specific, regional and global impacts. What might this mean for future investment in U.S. infrastructure – especially aroun…

Today we continue our conversation with Mike Sweeney, Global Head of Strategy for Cell & Gene Therapies and Direct to Patient products at QuickSTAT Global Life Science Logistics, on how to set up a robust CGT supply chain.  In Part 1, Mike described the explosion of cell and gene therapies reg…

Cell & Gene Therapies hold incredible potential for improving – if not saving – human lives. These CGT’s have been called “living drugs” and can heal diseased organs and – we hope – fight diseases that currently have no cure.  Because of these incredible possibilities, related research and dev…

In Part 2 of our conversation, Scott Ohanesian, QuickSTAT’s senior VP of Commercial Operations, and Mike Sweeney, QuickSTAT's Global Head of Strategy for CGT and Direct to Patient Products discuss the various challenges around the logistics of Cell & Gene Therapy – what to look out for and the …

Medical care and scientific research offer some of the most challenging – and developing – areas for global supply chain logistics. And few are more significant– in terms of potential for improving human life and logistics precision required – than Cell & Gene Therapy or CGT. These CGT “medica…

Cell & Gene Therapies hold incredible potential for improving – if not saving – human lives. These CGT’s have been called “living drugs” and can heal diseased organs and – we hope – fight diseases that currently have no cure.  Because of these incredible possibilities, related research and dev…

In Part 2, Mike Sweeney, QuickSTAT’s Global Head of Strategy for CGT and Direct to Patient products, offers specific supply chain design ideas and tactics to establish processes and overcome potential logistics roadblocks. He breaks down extraordinary case studies, and gives his views on what’s nex…

Critically ill patients increasingly can participate in life saving and life changing cell & gene therapy clinical trials without having to leave their homes with the Direct- to -Patient and Direct- from -Patient model. So how do you set up these supply chains? How do you mitigate risk? And how…